Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
|Videos|February 20, 2019
KRAS-Mutated Metastatic CRC
KRAS-Mutated Metastatic CRC
Advertisement
Case: A 38-year Old Woman WithKRAS-Mutated mCRC
Initial presentation
- A 38-year old woman was referred to gastroenterology after experiencing several bouts of bloody diarrhea
- PMH: unremarkable
- PE: unremarkable
Clinical workup
- Colonoscopy: suspicious sigmoid mass, partial obstruction
- Biopsy: poorly differentiated adenocarcinoma
- Imaging: CT scan of the chest/abdomen/pelvis revealed multiple small bilateral liver metastases
- Molecular testing on tissue biopsy:
- Positive forKRASexon 2 codon 12 mutation
- Negative forNRAS,BRAF
- Microsatellite-stable
- Diagnosis: stage IV colorectal cancer
- ECOG PS 0
Treatment
- She underwent laparoscopic sigmoid resection
- She was initiated on treatment with FOLFOX + bevacizumab; well-tolerated
- Follow-up imaging at 3 and 6 months showed a partial response
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
5